Merck, Foundation Medicine to build companion diagnostics for Keytruda
Companies to create tests for tissue-agnostic MSI-H and dMMR cancers using Foundation's next-generation sequencing platform.
Drugmakers increasingly target “baskets” of tumors based on mutations
A new report shows a steady growth in so-called "basket studies" in oncology, along with growing interest by the drug industry.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Why the immune system is our best bet to battle cancer
Immuno-oncology is on a roll, yet many questions remain unanswered. What incites an immune response and where does the future of the field lie?
In landmark move, FDA approves cancer drug for a biomarker not a tissue
“This is the first time the agency has approved a cancer treatment based on a common biomarker rather than the location in the body where the tumor originated," FDA announced. The question now: Is medicine ready?
Balance of power shifts with Merck’s Keytruda first-line therapy approval in lung cancer
The balance of power in the anti-PD-L1 therapy duel has once again shifted with a first-line therapy win by Keytruda for non-small cell lung cancer
Rookie of the Year: Forbes says Keytruda & Opdivo are 2014’s most important new drugs
What was the best new drug of 2014? Forbes‘ Matthew Herper chose two. Herper laid out a solid case for why two new – and highly similar – cancer drugs are standouts this year: Keytruda from Merck and Opdivo from Bristol-Myers Squibb. He writes: These two medicines represent a breakthrough in oncology: unlocking the immune system as a […]
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.